Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Xiujiao Shen

Sun Yat-sen University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 17, 2026 · JOURNAL ARTICLE

Pamiparib plus surufatinib with ctDNA monitoring in platinum-resistant ovarian cancer after PARP inhibitor progression: a phase Ib/II trial (POST-PARPi)

BMC Medicine

Phase Ib/II trial showing modest efficacy (46.7% 6-month PFS) with manageable toxicity in a treatment-refractory population, but limited by small sample size, low objective response rate, and single-arm design without comparator.

PromisingChuqiao Liang Jing Li Cheng Fang

Reported

Sample size29

6-month PFS rate46.7%

6-month PFS 95% CI24.4–66.2

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support